MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity

To identify genes whose loss confers resistance to CHK1 inhibitors, we perform genome-wide CRISPR-Cas9 screens in non-small-cell lung cancer (NSCLC) cell lines treated with the CHK1 inhibitor prexasertib (CHK1i). Five of the top six hits of the screens, MYBL2 (B-MYB), LIN54, FOXM1, cyclin A2 (CCNA2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Branigan, Timothy B., Kozono, David, Schade, Amy E., Deraska, Peter, Rivas, Hembly G., Sambel, Larissa, Reavis, Hunter D., Shapiro, Geoffrey I., D’Andrea, Alan D., DeCaprio, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970065/
https://www.ncbi.nlm.nih.gov/pubmed/33657372
http://dx.doi.org/10.1016/j.celrep.2021.108808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970065/
https://www.ncbi.nlm.nih.gov/pubmed/33657372
http://dx.doi.org/10.1016/j.celrep.2021.108808

Ejemplares similares